The New England journal of medicine, 2020-02, Vol.382 (6), p.514-524
- Slamon, Dennis J
- Neven, Patrick
- Chia, Stephen
- Fasching, Peter A
- De Laurentiis, Michelino
- Im, Seock-Ah
- Petrakova, Katarina
- Bianchi, Giulia V
- Esteva, Francisco J
- Martín, Miguel
- Nusch, Arnd
- Sonke, Gabe S
- De la Cruz-Merino, Luis
- Beck, J. Thaddeus
- Pivot, Xavier
- Sondhi, Manu
- Wang, Yingbo
- Chakravartty, Arunava
- Rodriguez-Lorenc, Karen
- Taran, Tetiana
- Jerusalem, Guy
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Slamon, Dennis J
- Neven, Patrick
- Chia, Stephen
- Fasching, Peter A
- De Laurentiis, Michelino
- Im, Seock-Ah
- Petrakova, Katarina
- Bianchi, Giulia V
- Esteva, Francisco J
- Martín, Miguel
- Nusch, Arnd
- Sonke, Gabe S
- De la Cruz-Merino, Luis
- Beck, J. Thaddeus
- Pivot, Xavier
- Sondhi, Manu
- Wang, Yingbo
- Chakravartty, Arunava
- Rodriguez-Lorenc, Karen
- Taran, Tetiana
- Jerusalem, Guy
- Titel
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2020-02, Vol.382 (6), p.514-524
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a cyclin-dependent kinase inhibitor, ribociclib. With longer follow-up, it is clear that fulvestrant and ribociclib also prolong overall survival.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1911149Titel-ID: cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_245119
- Format
- –
- Schlagworte
- Aged, Aminopyridines - administration & dosage, Aminopyridines - adverse effects, Aminopyridines/administration & dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Breast cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - mortality, Breast Neoplasms/drug therapy/mortality, Cancer therapies, Chemotherapy, Cyclin-dependent kinases, Drug Administration Schedule, Endocrine therapy, Epidermal growth factor, ErbB-2 protein, Female, Fulvestrant, Fulvestrant - administration & dosage, Fulvestrant - adverse effects, Fulvestrant/administration & dosage/adverse effects, Human health sciences, Humans, Hypotheses, Hypothesis testing, Kaplan-Meier Estimate, Middle Aged, Oncologie, oncology, Patients, Post-menopause, Postmenopause, Progression-Free Survival, Purines - administration & dosage, Purines - adverse effects, Purines/administration & dosage/adverse effects, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Sciences de la santé humaine, Statistical analysis, Survival, Targeted cancer therapy